|
|
|
|
Search: 
Latin American Herald Tribune
Venezuela Overview
Venezuelan Embassies & Consulates Around The World
Sites/Blogs about Venezuela
Venezuelan Newspapers
Facts about Venezuela
Venezuela Tourism
Embassies in Caracas

Colombia Overview
Colombian Embassies & Consulates Around the World
Government Links
Embassies in Bogota
Media
Sites/Blogs about Colombia
Educational Institutions

Stocks

Commodities
Crude Oil
US Gasoline Prices
Natural Gas
Gold
Silver
Copper

Euro
UK Pound
Australia Dollar
Canada Dollar
Brazil Real
Mexico Peso
India Rupee

Antigua & Barbuda
Aruba
Barbados
Cayman Islands
Cuba
Curacao
Dominica

Grenada
Haiti
Jamaica
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and the Grenadines

Belize
Costa Rica
El Salvador
Honduras
Nicaragua
Panama

Bahamas
Bermuda
Mexico

Argentina
Brazil
Chile
Guyana
Paraguay
Peru
Uruguay

What's New at LAHT?
Follow Us On Facebook
Follow Us On Twitter
Most Viewed on the Web
Popular on Twitter
Receive Our Daily Headlines


  HOME | USA

US Takes 1st Step Toward Approving Single-Dose Covid Vaccine

NEW YORK -- The Food and Drug Administration (FDA) said Wednesday that Johnson & Johnson's single-dose Covid-19 vaccine has met the efficacy and safety requirements to receive an emergency authorization for use in the United States, where the virus has claimed more than 500,000 lives.

On Friday, the independent experts on the FDA's Vaccines and Related Biological Products Advisory Committee will review the analysis and render a judgment.

If the panel signs off and the FDA approves the drug, the US Centers for Disease Control and Prevention Advisory Committee on Immunization Practices will address the details of delivering and administering the vaccine during an emergency meeting set for Feb. 28-March 1.

The Johnson & Johnson drug would be the third vaccine authorized for use in the US, joining the Pfizer/BioNTech and Moderna medications.

Besides leading the world in coronavirus deaths, the US also has the largest number of confirmed cases: 28.3 million.

The US has more than 28 million confirmed cases of Covid-19 Johnson & Johnson said late last month that its prospective Covid-19 vaccine has proven 66 percent effective in protecting against moderate to severe coronavirus and 85 percent effective in preventing cases requiring hospitalization.

Those findings emerged from a Phase 3 ENSEMBLE clinical trial including 43,783 participants in the US, South Africa and several Latin American countries.

The level of protection against moderate to severe Covid-19 infection varied by region: 72 percent in the US; 66 percent in Latin America; and 57 percent in South Africa, where a more dangerous variant of the virus has taken hold "Vaccine efficacy against central laboratory-confirmed moderate to severe/critical COVID-19 across all geographic areas in which the trial was conducted was 66.9 percent," the FDA said in the analysis released Wednesday.

Though the Johnson & Johnson medication more than meets the minimum standards for effectiveness set by the FDA, it falls short of the 90 percent efficacy achieved by the Pfizer/BioNTech and Moderna vaccines.

But the vaccine candidate developed by J&J's Janssen Pharmaceutical Companies has significant advantages over the Pfizer and Moderna drugs.

While the Pfizer and Moderna medications are two-dose vaccines and the former must be maintained at a super-low temperature, posing a logistical challenge, J&J said that the single-dose Janssen vaccine is "compatible with standard vaccine distribution channels."
 

Enter your email address to subscribe to free headlines (and great cartoons so every email has a happy ending!) from the Latin American Herald Tribune:

 

Copyright Latin American Herald Tribune - 2005-2021 © All rights reserved